Page 140 - Functional impairment and cues for rehabilitation of head and neck cancer patients -

138
Chapter 5
Appendix 7 Baseline characteristics by trismus at t2 and univariable analysis.
No trismus at t1
n = 55
Trismus at t1 n = 14
Univariable logistic regression analysis
OR (95%CI)
P value
Gender
Female Age at baseline Median (range)
2 (14)
64 (42-73)
0.4 (0.1-2.0) .272 1.1 (1.0-1.1) .154 .886
ACE-27
BMI Median (range) SMM Median (range) Sarcopenia
Tumor site
T classification
HPV status
7 (50)
0 (0)
0 (0)
24 (18-30) 44 (34-50)
1.6 (0.5-5.4) .421 NA NA NA NA 0.9 (0.7-1.0) .073 1.0 (0.9-1.1) .617
Treatment modality
Pretreatment trismus
4 (29) 1.0 1 (7)
Male
39 (71)
16 (29)
60 (39-77)
31 (56)
19 (35)
2 (4)
3 (6)
26 (17-44) 45 (22-64)
35 (64) 20 (36)
23 (42) 25 (46) 7 (13)
17 (31) 17 (31) 12 (22) 9 (16)
15 (28) 38 (72) 2
24 (44) 9 (16) 22 (40)
52 (96) 2 (4)
1
12 (86) 1.0
0 1 2 3
No Yes
Base of tongue Tonsil
Other
T1 T2 T3 T4
Negative Positive Unknown
RT
RT + cetuximab RT + cisplatin
No
Yes Unknown
7 (50) 1.0
NB: Not all percentages sum up exactly to 100% due to rounding.
Abbreviations: BMI = body mass index, CI = confidence interval, HPV = human papilloma virus, FOIS = functional oral intake scale, OR = odds ratio, other = soft palate, uvula, oropharyngeal wall, vallecula or pharyngeal arch,
RT = radiotherapy, sarcopenia = SMM below 43.2 cm2/m2, SMM = skeletal muscle mass.
8 (57) 1.0
6 (43)
2 (14) 1.0
8 (57) 4 (29)
3.7 (0.7-19.2) .122 6.6 (1.0-43.8) .052 .164
2 (14) 1.0
2 (14) 7 (50) 3 (21)
1.0 (0.1-7.9) 1.000 5.0 (0.9-28.2) .071 2.8 (0.4-10.2) .298
2 (14) 1.0
12 (86) 0
2.4 (0.5-11.9) .294
.272
0.7 (0.1-6.8) .732
2.5 (0.7-9.1) .180 5.2 (0.7-41.4) .119
9 (64)
10 (83) 2 (17) 2
1.3 (0.4-4.3) .655 .142